Shares of Avadel Pharmaceuticals plc (AVDL) are soaring over 37% in pre-market today, after the company announced positive topline data from its pivotal Phase 3 REST-ON trial assessing the safety and efficacy of FT218, an investigational, once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy.
from RTT - Before the Bell https://ift.tt/2yS8nsr
via IFTTT
No comments:
Post a Comment